Még nem toboroz
A trial to learn how well Dato-DXd works and how safe it is with other anticancer drugs in adults with TROP2 NMR-positive non-small cell lung cancer
2025-524836-21-00· 2. fázis· AstraZeneca AB· Forrás
Toboroz
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
2024-518365-10-00· 3. fázis· F. Hoffmann-La Roche AG· Forrás
Még nem toboroz
Personnalized Immunotherapy in Patients With Stage III Non-small Cell Lung Cancer
NCT07759492· 2. fázis· Intergroupe Francophone de Cancerologie Thoracique· Forrás
Még nem toboroz
Evaluation of the Efficacy and Safety of Bimekizumab (BZK) or Adalimumab (ADA) in the Treatment of Anterior Chest Wall Pain Associated With Active Axial Spondyloarthritis Refractory to NSAIDs With Hypothesis of Superiority of Bimekizumab
NCT07836283· 3. fázis· University Hospital, Rouen· Forrás
Még nem toboroz
Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease
NCT07420439· 2. fázis· Intergroupe Francophone de Cancerologie Thoracique· Forrás
Még nem toboroz
Rollover Study for Participants Who Have Completed a Previous Clinical Study with Anifrolumab (Saphnelo) and Clinically Benefited from Continued Treatment.
2026-526419-13-00· 3. fázis· AstraZeneca AB· Forrás
Toboroz
Phase 2, Multicenter, Open label, Platform Study investigating ASP3082 in patients with Metastatic/Locally Advanced Non-Small-Cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), with biomarker analysis to characterize response/resistance (UNLOCK ASP3082)
2025-522533-54-00· 2. fázis· Institut Gustave Roussy· Forrás
Toboroz
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
NCT07361510· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
NCT07258407· 1/2. fázis· T.O.A.D. Oncology SA· Forrás
Toboroz
Phase 3 Study of Xaluritamig Plus Abiraterone vs Investigator's Choice in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
2025-520555-89-00· 3. fázis· Amgen Inc.· Forrás
Fut, nem toboroz
A Study of Subcutaneous Nivolumab plus Intravenous Ipilimumab and Chemotherapy in Participants with Previously Untreated Metastatic or Recurrent NSCLC
2024-520108-25-00· 2. fázis· Bristol-Myers Squibb Services Unlimited Company· Forrás
Toboroz
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
NCT06919965· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
NCT06855771· 2. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803· 3. fázis· AstraZeneca· Forrás
Toboroz
Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer
2024-515884-69-00· 3. fázis· Gilead Sciences Inc.· Forrás
Toboroz
Evaluation of 200 mg of Rituximab Every 6 Months as Maintenance Treatment of Rituximab-treated Patients With Rheumatoid Arthritis
NCT06906549· 4. fázis· University Hospital, Strasbourg, France· Forrás
Toboroz
Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors
NCT05974774· 3. fázis· European Organisation for Research and Treatment of Cancer - EORTC· Forrás
Toboroz
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
PRODIGE 90 - FFCD 22024 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatellite unstable or mismatch repair-deficient locally advanced rectal cancer patients: a randomized phase II trial
2024-510772-20-00· 2. fázis· Centre Hospitalier Universitaire De Dijon· Forrás
Még nem toboroz
Stop Treatment in gout
2024-515714-40-00· 2. fázis· Assistance Publique Hopitaux De Paris· Forrás
Fut, nem toboroz
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824· 3. fázis· Genmab· Forrás
Toboroz
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) after immunotherapy failure.
2023-509340-10-00· 3. fázis· OSE Immunotherapeutics· Forrás
Toboroz
QUIDOSE. Randomized controlled trial testing the efficacy of hydroxychloroquine combined with low dose corticosteroid therapy in pulmonary sarcoidosis
NCT05247554· 3. fázis· Assistance Publique Hopitaux De Paris· Forrás
Toboroz
Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis
NCT05841758· 4. fázis· Hospices Civils de Lyon· Forrás
Toboroz
CARE1: FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
2023-503317-29-00· 3. fázis· Institut Gustave Roussy· Forrás
Fut, nem toboroz
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT06329401· 2. fázis· Avalyn Pharma Inc.· Forrás
Toboroz
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
NCT06074588· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation
2022-502959-54-00· 3. fázis· Dizal Pharmaceutical Co. Ltd.· Forrás
Fut, nem toboroz
SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate Cancer
NCT05826509· 2. fázis· Institut Claudius Regaud· Forrás
Toboroz
Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
NCT05751798· 1/2. fázis· OSE Immunotherapeutics· Forrás
Fut, nem toboroz
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT05170204· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
NCT04916613· 3. fázis· UNICANCER· Forrás
Toboroz
Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary
NCT04325425· 2. fázis· Centre Hospitalier Universitaire Dijon· Forrás